Gary S. Gray

6.3k total citations · 4 hit papers
36 papers, 5.4k citations indexed

About

Gary S. Gray is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gary S. Gray has authored 36 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 10 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gary S. Gray's work include T-cell and B-cell Immunology (17 papers), Immune Cell Function and Interaction (11 papers) and Immunotherapy and Immune Responses (10 papers). Gary S. Gray is often cited by papers focused on T-cell and B-cell Immunology (17 papers), Immune Cell Function and Interaction (11 papers) and Immunotherapy and Immune Responses (10 papers). Gary S. Gray collaborates with scholars based in United States, Hungary and France. Gary S. Gray's co-authors include Gordon J. Freeman, Vassiliki A. Boussiotis, Theodore E. Maione, Lee M. Nadler, Lisa A. Lombard, John G. Gribben, David M. Harlan, Allan D. Kirk, Thomas A. Davis and Nicholas Armstrong and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Gary S. Gray

36 papers receiving 5.2k citations

Hit Papers

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rej... 1990 2026 2002 2014 1997 1993 1990 1995 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
    1997 776 citations Allan D. Kirk, David M. Harlan et al. profile →
  2. Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
    1993 773 citations Gordon J. Freeman, Gary S. Gray et al. profile →
  3. Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides
    1990 577 citations Theodore E. Maione, Gary S. Gray et al. profile →
  4. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4
    1995 507 citations Gordon J. Freeman, Paul D. Rennert et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary S. Gray United States 27 3.2k 1.2k 1.0k 582 578 36 5.4k
Diane Hollenbaugh United States 32 4.4k 1.4× 1.7k 1.4× 891 0.9× 445 0.8× 775 1.3× 75 7.0k
P S Linsley United States 21 4.9k 1.5× 740 0.6× 1.2k 1.2× 620 1.1× 340 0.6× 23 6.1k
P L Amlot United Kingdom 38 2.3k 0.7× 954 0.8× 1.8k 1.8× 708 1.2× 619 1.1× 101 6.0k
Rudolf A. Manz Germany 36 3.7k 1.2× 1.1k 0.9× 805 0.8× 790 1.4× 267 0.5× 77 6.0k
G S Gray United States 29 3.6k 1.1× 865 0.7× 764 0.8× 367 0.6× 381 0.7× 37 4.9k
Claudia Benike United States 28 4.9k 1.5× 1.6k 1.4× 1.8k 1.7× 904 1.6× 459 0.8× 50 6.3k
Elisabeth H. Weiss Germany 44 3.9k 1.2× 1.4k 1.2× 549 0.5× 428 0.7× 371 0.6× 133 5.9k
Nitin K. Damle United States 41 4.7k 1.4× 1.1k 0.9× 1.7k 1.7× 1.3k 2.3× 346 0.6× 73 6.9k
Jonathan C. Poe United States 37 4.2k 1.3× 917 0.8× 855 0.8× 1.1k 1.9× 191 0.3× 62 5.8k
T. A. Waldmann United States 30 3.1k 1.0× 800 0.7× 882 0.9× 976 1.7× 227 0.4× 48 4.8k

Countries citing papers authored by Gary S. Gray

Since Specialization
Citations

This map shows the geographic impact of Gary S. Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary S. Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary S. Gray more than expected).

Fields of papers citing papers by Gary S. Gray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary S. Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary S. Gray. The network helps show where Gary S. Gray may publish in the future.

Co-authorship network of co-authors of Gary S. Gray

This figure shows the co-authorship network connecting the top 25 collaborators of Gary S. Gray. A scholar is included among the top collaborators of Gary S. Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary S. Gray. Gary S. Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilcox, Marsha, Adam Savitz, Anjené Addington, et al.. (2018). The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data. Schizophrenia. 4(1). 14–14. 1 indexed citations
2.
Ross, Jeffrey S., Karen Gray, Iain J. Webb, et al.. (2005). Antibody-based therapeutics: Focus on prostate cancer. Cancer and Metastasis Reviews. 24(4). 521–537. 31 indexed citations
3.
Ross, Jeffrey S. & Gary S. Gray. (2004). Targeted therapy for cancer: the HER-2/neu and Herceptin story.. PubMed. 17(6). 333–40. 26 indexed citations
4.
Gray, Karen, David P. Schenkein, Barry R. Greene, et al.. (2003). Antibody-based therapeutics in oncology. Expert Review of Anticancer Therapy. 3(1). 107–121. 37 indexed citations
5.
Montgomery, Sean P., He Xu, Douglas K. Tadaki, et al.. (2002). Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 74(10). 1365–1369. 51 indexed citations
6.
Kirk, Allan D., Douglas K. Tadaki, Abbie Celniker, et al.. (2001). INDUCTION THERAPY WITH MONOCLONAL ANTIBODIES SPECIFIC FOR CD80 AND CD86 DELAYS THE ONSET OF ACUTE RENAL ALLOGRAFT REJECTION IN NON-HUMAN PRIMATES1. Transplantation. 72(3). 377–384. 108 indexed citations
7.
Theriault, Betty, J. Richard Thistlethwaite, Matteo Levisetti, et al.. (1999). INDUCTION, MAINTENANCE, AND REVERSAL OF STREPTOZOTOCIN-INDUCED INSULIN-DEPENDENT DIABETES MELLITUS IN THE JUVENILE CYNOMOLGUS MONKEY (Macaca fascilularis)1. Transplantation. 68(3). 331–337. 52 indexed citations
8.
Ling, Vincent, Paul W. Wu, Heather Finnerty, et al.. (1999). Complete Sequence Determination of the Mouse and Human CTLA4 Gene Loci: Cross-Species DNA Sequence Similarity beyond Exon Borders. Genomics. 60(3). 341–355. 59 indexed citations
9.
Lee, Kwang, Gary S. Gray, Richard Zollner, et al.. (1999). Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.. PubMed. 59(19). 4964–72. 46 indexed citations
10.
Rathmell, Jeffrey C., et al.. (1998). Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28. The Journal of Experimental Medicine. 188(1). 199–204. 162 indexed citations
11.
Blair, Patrick J., James L. Riley, Bruce L. Levine, et al.. (1998). Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction. The Journal of Immunology. 160(1). 12–15. 107 indexed citations
12.
Ling, Vincent, et al.. (1998). Embryonic Stem Cells and Embryoid Bodies Express Lymphocyte Costimulatory Molecules. Experimental Cell Research. 241(1). 55–65. 19 indexed citations
13.
Perrin, P J, Dorothy E. Scott, Gary S. Gray, et al.. (1996). Opposing effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on experimental allergic encephalomyelitis. Journal of Neuroimmunology. 65(1). 31–39. 40 indexed citations
14.
Lenschow, Deborah J., Yijun Zeng, Karen S. Hathcock, et al.. (1995). INHIBITION OF TRANSPLANT REJECTION FOLLOWING TREATMENT WITH ANTI-B7-2 AND ANTI-B7-1 ANTIBODIES. Transplantation. 60(10). 1171–1178. 143 indexed citations
15.
Green, Jonathan M., Patricia J. Noel, Anne I. Sperling, et al.. (1994). Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1(6). 501–508. 333 indexed citations
16.
17.
Myers, Jill A., Gary S. Gray, David Peters, et al.. (1991). Expression and purification of active recombinant platelet factor 4 from a cleavable fusion protein. Protein Expression and Purification. 2(2-3). 136–143. 15 indexed citations
18.
Gray, Gary S., et al.. (1990). Envelope gene sequence of HTLV-1 isolate MT-2 and its comparison with other HTLV-1 isolates. Virology. 177(1). 391–395. 68 indexed citations
19.
Daly, Thomas J., Kathleen Sue Cook, Gary S. Gray, Theodore E. Maione, & James R. Rusche. (1989). Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature. 342(6251). 816–819. 331 indexed citations
20.
Gray, Gary S., et al.. (1989). Nucleotide sequence of the core (gag) gene from HTLV-1 isolate MT-2. Nucleic Acids Research. 17(19). 7998–7998. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diane Hollenbaugh Breakdown of academic impact, for papers by P S Linsley Breakdown of academic impact, for papers by P L Amlot Breakdown of academic impact, for papers by Rudolf A. Manz Breakdown of academic impact, for papers by G S Gray Breakdown of academic impact, for papers by Claudia Benike Breakdown of academic impact, for papers by Elisabeth H. Weiss Breakdown of academic impact, for papers by Nitin K. Damle Breakdown of academic impact, for papers by Jonathan C. Poe Breakdown of academic impact, for papers by T. A. Waldmann
Rankless by CCL
2026